Methods for modulating an immune response
AssigneeCue Biopharma, Inc.
InventorsRonald D. Seidel, III, Rodolfo J. Chaparro
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.
Claims16
A method of treating cancer in an individual, the method comprising administering to the individual (i) an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is an antibody that targets CTLA-4, and (ii) a composition comprising a protein, wherein the protein comprises two heterodimers, wherein each heterodimer comprises:
- a) a first polypeptide comprising:
- i) a cancer-associated epitope other than a human papilloma virus-16 (HPV16) cancer-associated epitope;
- ii) a linker comprising the amino acid sequence set forth in any one of SEQ ID NOs:
- 205-209;
- and iii) a β2-microglobulin (β2M) polypeptide;
- and b) a second polypeptide comprising:
- i) two immunomodulatory polypeptides, wherein each of the two immunomodulatory polypeptides is a variant IL-2 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:49;
- ii) a major histocompatibility complex (MHC) class I heavy chain polypeptide;
- and iii) an immunoglobulin (Ig) Fc polypeptide, wherein the two heterodimers are joined by one or more disulfide bonds between the Ig Fc polypeptides, wherein the immune checkpoint inhibitor and the composition comprising the protein are administered at the same time or at different times.
Dependencies are inferred from the claim text.